These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 11383648)
1. Toxicity outcome after three-dimensional conformal radiotherapy for early stage prostatic cancer. Kurtman C Radiat Med; 2001; 19(2):89-92. PubMed ID: 11383648 [TBL] [Abstract][Full Text] [Related]
2. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Karlsdóttir A; Johannessen DC; Muren LP; Wentzel-Larsen T; Dahl O Radiother Oncol; 2004 Apr; 71(1):43-53. PubMed ID: 15066295 [TBL] [Abstract][Full Text] [Related]
3. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526 [TBL] [Abstract][Full Text] [Related]
5. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881 [TBL] [Abstract][Full Text] [Related]
6. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428 [TBL] [Abstract][Full Text] [Related]
7. Late toxicity after conformal and intensity-modulated radiation therapy for prostate cancer: impact of previous surgery for benign prostatic hyperplasia. Odrazka K; Dolezel M; Vanasek J; Vaculikova M; Zouhar M; Sefrova J; Paluska P; Vosmik M; Kohlova T; Kolarova I; Navratil P; Brodak M; Prosvic P; Hoffmann P Int J Urol; 2010 Sep; 17(9):784-90. PubMed ID: 20604816 [TBL] [Abstract][Full Text] [Related]
8. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549 [TBL] [Abstract][Full Text] [Related]
9. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Valdagni R; Italia C; Montanaro P; Lanceni A; Lattuada P; Magnani T; Fiorino C; Nahum A Radiother Oncol; 2005 Apr; 75(1):74-82. PubMed ID: 15878104 [TBL] [Abstract][Full Text] [Related]
10. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy? Sanguineti G; Cavey ML; Endres EJ; Franzone P; Barra S; Parker BC; Marcenaro M; Colman M; Agostinelli S; Foppiano F; Vitale V Strahlenther Onkol; 2006 Sep; 182(9):543-9. PubMed ID: 16944377 [TBL] [Abstract][Full Text] [Related]
11. [Acute toxicity in 50 patients with prostate cancer treated with conformal radiation therapy]. Nasr E; Merhej S; Nehme Nasr D; Fares G J Med Liban; 2001; 49(6):325-8. PubMed ID: 12744634 [TBL] [Abstract][Full Text] [Related]
12. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):397-405. PubMed ID: 15890581 [TBL] [Abstract][Full Text] [Related]
13. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity. Karlsdóttir A; Muren LP; Wentzel-Larsen T; Dahl O Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1478-86. PubMed ID: 18060703 [TBL] [Abstract][Full Text] [Related]
14. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237 [TBL] [Abstract][Full Text] [Related]
15. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity. Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959 [TBL] [Abstract][Full Text] [Related]
16. Comparison of late rectal toxicity from conventional versus three-dimensional conformal radiotherapy for prostate cancer: analysis of clinical and dosimetric factors. Lee CM; Lee RJ; Handrahan DL; Sause WT Urology; 2005 Jan; 65(1):114-9. PubMed ID: 15667875 [TBL] [Abstract][Full Text] [Related]
17. Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer. Aillères N; Azria D; Thézenas S; Barbier N; Fenoglietto P; Delard R; Hay MH; Dubois JB Cancer Radiother; 2004 Apr; 8(2):59-69. PubMed ID: 15063872 [TBL] [Abstract][Full Text] [Related]
18. Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial. Koper PC; Jansen P; van Putten W; van Os M; Wijnmaalen AJ; Lebesque JV; Levendag PC Radiother Oncol; 2004 Oct; 73(1):1-9. PubMed ID: 15465140 [TBL] [Abstract][Full Text] [Related]
19. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Rosenzweig KE; Fox JL; Yorke E; Amols H; Jackson A; Rusch V; Kris MG; Ling CC; Leibel SA Cancer; 2005 May; 103(10):2118-27. PubMed ID: 15830346 [TBL] [Abstract][Full Text] [Related]
20. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma. Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]